BUSINESS
FOMC minutes raise concerns over sticky inflation; push 'higher-for-longer' narrative on rate cuts
The US Fed policymakers expressed apprehensions over the rate-cut timeline as inflation remains above the US central bank's 2 percent target, despite cooling significantly.
BUSINESS
Medanta stock tanks 13% in 3 days after strong Q4 results, as margin, valuation concerns weigh
Even though long-term growth prospects remain intact for Global Health, slow near-term margin expansion due to consistent capex, along with the pricey valuations of the stock has triggered a selloff in the counter.
BUSINESS
Sun Pharma Q4 preview: Strong speciality drug sales, Revlimid contribution, domestic growth to aid earnings
BUSINESS
Hindustan Aeronautics shares can't stop flying and brokerages support the flight
Brokerages are gung-ho about Hindustan Aeronautics, primarily due to the defence company's strong growth visibility, robust order book, resilient earnings performance and plenty export opportunities.
BUSINESS
Closing Bell: Sensex gains 90 pts, Nifty ends near 22,500 on special trading session
Sensex Today | All sectors ended the special trading session in the green, with capital goods, PSUs, industrials and media leading from the up. Metals, PSU banks, pharma and realty also posted decent gains.
BUSINESS
TBO Tek arrives in style, lists at 55% premium on market debut
Several marquee names like Nomura Funds, Blackrock Global Funds, Fidelity Funds, Goldman Sachs, HSBC Global, ICICI Prudential MF were among the few that participated in TBO Tek's IPO.
BUSINESS
JSPL shares rise 4% as brokerages give thumbs up to firm's solid Q4 earnings, strong growth prospects
Brokerages painted a strong growth outlook for Jindal Steel and Power amid expectations of robust EBITDA and volume growth due to rising steel prices and completion of most of the planned capex in FY25.
BUSINESS
UPL's near-term earnings pressure bigger worry for brokerages even as firm set for $500-mn rights issue
Even though UPL is trying hard to reduce its staggering debt through the issue of Rs 4,200-crore rights issue, brokerages remain cautious due to the persisting industry weakness and pressure on the firm's margins.
BUSINESS
MSCI May rejig could attract $2 billion inflows; Indus Towers, PB Fintech, Mankind Pharma likely inclusions
India's weight in the MSCI Emerging Market Index stands closer to 18 percent, marking a significant leap from just around 8 percent in early 2020. Nuvama Alternative expects it to rise further and hit the 20 percent mark in the second half of 2024.
BUSINESS
Dr Lal PathLabs' strong Q4 results, upbeat commentary paints a comeback picture; stock up 8%
According to analysts, the biggest positive from Dr Lal PathLabs' commentary is their guidance to achieve double-digit revenue growth in FY25 without price hikes.
BUSINESS
Cipla's strong US pipeline, steady Q4 earnings and hopes of easing regulatory snags drive bullishness
Cipla plans to launch 12 assets in peptides and complex generics space and 5 in the respiratory segment over FY25-27, which brokerages believe will secure its growth path for the next 3-4 years.
BUSINESS
Vijaya Diagnostic's strong Q4 results lift shares to record high, brokerages bullish
Brokerages have a bullish stance on Vijaya Diagnostic, forecasting a rosy picture for the near-term, cemented on the company's robust growth visibility, strong execution and expansion plans.
BUSINESS
Cipla Q4 results preview: Revenue boost likely from strong US sales, net profit to jump from low base
Cipla's US sales likely to surge in Q4, driven by the contribution from Revlimid, along with a stable market share in Albuterol (respiratory drug) and an expansion in Lanreotide (hormonal drug) and Brovana (inhalation drug)
BUSINESS
Lupin set for strong growth, but expensive stock valuations may cap upside
With a strong US launch pipeline, benign price erosion and focus on complex generics, Lupin sits on tracks for a robust growth trajectory. However, the stretched valuations of the stock will hinder the scope for further upside.
BUSINESS
Dr Reddy's healthy Q4 results fail to impress brokerages amid lack of growth triggers
While Revlimid push helped Dr Reddy's report healthy Q4 earnings, a lack of strong US launch pipeline, high R&D costs and weakness in base business are expected to put near-term pressure on the drugmaker.
BUSINESS
Route Mobile drops 5% as Q4 earnings disappoint; brokerages hopeful of better times
While industry headwinds dragged Route Mobile's Q4 earnings, a line-up of big deals in FY25 is expected to aid synergies and bring better times for the company in the coming fiscal.
BUSINESS
Dr Reddy's Q4 preview: US sales, Revlimid contribution to deliver another steady quarter
While earnings for Dr Reddy's is expected to remain strong in Q4, an uptick in R&D investments and new initiative may cap the drugmaker's margin expansion.
BUSINESS
Auto, private banks, telecom among sectors trading at a discount, says MOFSL
Apart from five sectors, which constitute one-third of the overall market, all others are trading at a premium to their historical long-period averages, MOFSL noted
BUSINESS
Ajanta Pharma shares zoom 14% on stellar Q4 earnings, buyback plans
Ajanta Pharma approved its fourth buyback plan in as many years, offering a premium of 25 percent to stakeholders.
BUSINESS
Sensex, Nifty end with mild gains as banks sell off, midcaps stay upbeat
Fed Chair Jerome Powell's remarks over the unlikelihood of more rate hikes eased concerns across global markets, there by lifting sentiment for stocks.
BUSINESS
Havells' strong Q4 results impress Street, but expensive valuation plays spoilsport
Brokerages stand impressed with Havells India's strong growth on all key parameters in Q4. But the expensive valuations of the stock raise concerns of its potential upside despite the company's strong growth prospects.
BUSINESS
Q4 earnings: Positive surprises from Nifty 50 banking majors fire up indices
The Q4 earnings season has been a mixed bag so far, but it is the private banking pack that has delivered maximum positive surprises.
BUSINESS
Nifty seen in 22,350-22,700 range as May rollover shows FIIs cautious, pruning long positions
FIIs taking hedged positions amid expectations of high volatility due to general elections and Q4 earnings.
BUSINESS
Apollo Hospitals sinks 8% as Apollo HealthCo's valuation in Advent deal a letdown for Street
While the lower-than-expected valuations assigned to Apollo HealthCo came as a negative surprise, analysts remain hopeful of reduced cash burn and rapid expansion for the Apollo Hospitals' arm.
